GO:0006011 UDP-alpha-D-glucose metabolic process: Glycosylation and Drug Target Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006011 describes the chemical reactions and pathways involving UDP-alpha-D-glucose, the activated sugar donor used in glycosylation and polysaccharide biosynthesis [1,4].
• UDP-glucose is interconverted with UDP-glucuronate by UDP-glucose 6-dehydrogenase (UGDH), a key enzyme in glycosaminoglycan and drug-conjugation pathways [4,5].
• UGDH is a potential drug target in cancer, and its inhibition reduces glioblastoma growth and migration [1,4].
• UDP-glucose-dependent glycosyltransferases are widely used in engineered microbes to glucosylate flavonoids and other small molecules [6,7,8].
• The pathway is studied with enzyme assays, structural biology, metabolomics, and CRISPR-based gene editing [1,2,5].
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal testing of UDP-glucose metabolic genes in disease and biotechnology [1,6].
Description
UDP-alpha-D-glucose metabolic process (GO:0006011) is the set of biochemical reactions and pathways that produce, interconvert, and consume UDP-alpha-D-glucose, an activated nucleotide sugar composed of alpha-D-glucose linked to uridine diphosphate [1,4]. This pathway supplies the glucose donor for glycosyltransferases that build glycans, glycoproteins, and polysaccharides, and it feeds into the synthesis of UDP-glucuronate and other nucleotide sugars [4,5]. Because UDP-glucose sits at the intersection of energy metabolism, glycosylation, and detoxification, it is relevant to cancer biology, microbial pathogenesis, and industrial biocatalysis [1,3,6]. Researchers study GO:0006011 to understand how cells allocate sugar donors, how pathogens build capsular polysaccharides, and how engineered microbes can glucosylate valuable compounds [3,6,7,8]. The pathway is also a drug-discovery target because UDP-glucose 6-dehydrogenase (UGDH) supports tumor growth and migration [1,4].
UDP-alpha-D-glucose metabolic process At A Glance
| GO ID | GO:0006011 |
|---|---|
| GO term | UDP-alpha-D-glucose metabolic process |
| Ontology | biological_process |
| Synonym | UDP-glucose metabolism |
| Definition | The chemical reactions and pathways involving UDP-alpha-D-glucose, a substance composed of alpha-D-glucose in glycosidic linkage with uridine diphosphate. |
| Major function | Production and utilization of UDP-glucose as a glycosyl donor and precursor of UDP-glucuronate and other nucleotide sugars [1,4,5]. |
| Key enzyme | UDP-glucose 6-dehydrogenase (UGDH), which oxidizes UDP-glucose to UDP-glucuronate [4,5]. |
| Related processes | Glycosylation, glycosaminoglycan biosynthesis, capsular polysaccharide formation, and flavonoid glucosylation [3,6,7,8]. |
| Disease relevance | Cancer growth and migration, especially glioblastoma, and potential drug-target status [1,4]. |
What Is GO:0006011?
GO:0006011, UDP-alpha-D-glucose metabolic process, is defined as the chemical reactions and pathways involving UDP-alpha-D-glucose, a substance composed of alpha-D-glucose in glycosidic linkage with uridine diphosphate. In practice, this includes the formation of UDP-glucose from glucose-1-phosphate and UTP, its use as a glycosyl donor, its oxidation to UDP-glucuronate, and its interconversion with other nucleotide sugars [1,4,5].
Why Is UDP-alpha-D-glucose metabolic process Important in Cell Biology?
UDP-alpha-D-glucose metabolic process is important because UDP-glucose is a central activated sugar donor required for glycosylation, polysaccharide biosynthesis, and detoxification, and its metabolic enzymes are linked to human disease and biotechnology [1,4,6]. UGDH, the enzyme that converts UDP-glucose to UDP-glucuronate, is a potential drug target, and its inhibition suppresses glioblastoma growth and migration [1,4]. The same pathway is exploited in engineered bacteria to glucosylate flavonoids and other bioactive molecules, making it valuable for synthetic biology and pharmaceutical production [6,7,8].
• Supplies UDP-glucose for glycosyltransferases that modify proteins, lipids, and small molecules [1,4].
• Feeds UDP-glucuronate synthesis, which supports glycosaminoglycan production and drug conjugation [4,5].
• UGDH is a potential drug target in cancer, including glioblastoma [1,4].
• UDP-glucose-dependent enzymes are used in engineered microbes to glucosylate flavonoids [6,7,8].
• The pathway contributes to capsular polysaccharide biosynthesis in pathogens such as Campylobacter jejuni.
• Structural studies of UDP-glucose dehydrogenases inform inhibitor design and biocatalyst engineering [2,5].
• Metabolic engineering of UDP-glucose supply improves production of glucosides in E. coli [6,7].
• CRISPR-based editing enables causal tests of UDP-glucose metabolic genes in disease models [1,6].
What Happens During UDP-alpha-D-glucose metabolic process?
Synthesis of UDP-alpha-D-glucose
In simple terms: The cell attaches glucose to a carrier molecule called UTP to make UDP-glucose.
UDP-alpha-D-glucose is generated by the transfer of glucose-1-phosphate to UTP, producing the activated sugar donor used in glycosylation reactions [1,4]. This step is essential because UDP-glucose is the substrate for glycosyltransferases and for UDP-glucose 6-dehydrogenase [4,5].
Oxidation to UDP-glucuronate by UGDH
In simple terms: An enzyme called UGDH changes UDP-glucose into UDP-glucuronate, a related sugar donor.
UDP-glucose 6-dehydrogenase (UGDH) catalyzes the NAD+-dependent oxidation of UDP-glucose to UDP-glucuronate, a key precursor for glycosaminoglycans and glucuronidation [4,5]. Structural and biochemical studies show that cofactor binding triggers an allosteric switch that activates human UGDH.
Use as a glycosyl donor
In simple terms: UDP-glucose hands its glucose to other molecules, modifying them.
UDP-glucose serves as a glucose donor for glycosyltransferases that glucosylate flavonoids, synthesize capsular polysaccharides, and modify diverse acceptors [3,6,7,8]. In engineered E. coli, UDP-glucose-dependent glucosylation produces isoflavonoid and resveratrol glucosides [6,7].
Interconversion with other nucleotide sugars
In simple terms: UDP-glucose can be converted into other sugar carriers used in cell wall and glycan synthesis.
UDP-glucose is interconverted with other nucleotide sugars, including UDP-glucuronate and UDP-arabinofuranoside, supporting capsular polysaccharide biosynthesis and glycan diversity [3,4]. These interconversions expand the repertoire of sugar donors available for glycosylation [3,5].
Biotechnological cascade reactions
In simple terms: Scientists use enzymes from this pathway in one-pot reactions to make useful compounds.
Cascade biocatalysis systems use UDP-glucose-dependent enzymes to convert sucrose into bioactive naringenin glucosides and quercetin rhamnoside, demonstrating the pathway's utility in synthetic biology. Single-vessel enzymatic synthesis of resvera-A glucosides further illustrates practical applications.
Key Genes Involved in GO:0006011 UDP-alpha-D-glucose metabolic process
The following genes and proteins are central to UDP-alpha-D-glucose metabolic process and its downstream applications.
| Gene | Major Role | Research Relevance |
|---|---|---|
| UGDH | Oxidizes UDP-glucose to UDP-glucuronate | Drug target in glioblastoma; allosteric regulation studied [1,4,5] |
| UGP2 | Synthesizes UDP-glucose from glucose-1-phosphate and UTP | Supplies substrate for glycosylation and UGDH [1,4] |
| UGT1A | Glucosylates small molecules using UDP-glucose | Flavonoid and drug glucosylation [6,7] |
| UGT2B | Glucosylates flavonoids and xenobiotics | Engineered E. coli glucosylation |
| CalS8 | TDP-glucose dehydrogenase in calicheamicin biosynthesis | Structural model for UDP-glucose dehydrogenases |
| CjUGD | UDP-glucose dehydrogenase in Campylobacter jejuni | Capsular polysaccharide biosynthesis |
| CjUGB | UDP-glucose 4-epimerase in C. jejuni | UDP-arabinofuranoside synthesis |
| CjUGA | UDP-glucose pyrophosphorylase in C. jejuni | Capsular polysaccharide pathway |
| GALE | UDP-glucose 4-epimerase | Interconverts UDP-glucose and UDP-galactose [3,4] |
| PGM | Phosphoglucomutase | Feeds glucose-1-phosphate into UDP-glucose synthesis |
| GNPTAB | GlcNAc-1-phosphotransferase | Glycosylation-related, not direct UDP-glucose enzyme |
| B4GALT | Beta-1,4-galactosyltransferase | Uses UDP-galactose derived from UDP-glucose |
| EXT1 | Glycosyltransferase for heparan sulfate | Uses UDP-glucuronate from UGDH |
| EXT2 | Glycosyltransferase for heparan sulfate | Uses UDP-glucuronate from UGDH |
| CHSY1 | Chondroitin sulfate synthase | Uses UDP-glucuronate from UGDH |
| CSGALNACT1 | Chondroitin sulfate N-acetylgalactosaminyltransferase | Glycosaminoglycan biosynthesis |
| HAS2 | Hyaluronan synthase | Uses UDP-glucuronate and UDP-GlcNAc |
How Is UDP-alpha-D-glucose metabolic process Regulated?
UDP-alpha-D-glucose metabolic process is regulated at multiple levels. UGDH activity is controlled by cofactor binding, which triggers an allosteric switch to activate the human enzyme. Substrate availability, including glucose-1-phosphate and UTP, influences UDP-glucose synthesis, while downstream glycosyltransferases compete for UDP-glucose as a donor [4,6]. In engineered systems, pathway flux can be redirected by expressing specific glucosyltransferases and by supplying sucrose as a feedstock [7,8].
UDP-alpha-D-glucose metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| UGDH | Glioblastoma growth and migration | UGDH knockout glioblastoma cell line |
| UGDH | Cancer drug target | Point-mutation of catalytic residues [1,4] |
| CjUGD | Campylobacter jejuni capsular polysaccharide | Knockout in C. jejuni |
| UGP2 | Glycosylation defects | Knockout in mammalian cells |
| UGT1A | Flavonoid metabolism | Overexpression in E. coli |
Glioblastoma and Cancer
UDP-glucose 6-dehydrogenase (UGDH) supports glioblastoma growth and migration, and targeting UGDH inhibits these processes. UGDH is considered a potential drug target because its activity affects glycosaminoglycan biosynthesis and signaling pathways that promote tumor progression [1,4].
Bacterial Pathogenesis
UDP-glucose metabolic enzymes contribute to capsular polysaccharide biosynthesis in Campylobacter jejuni, which is important for bacterial virulence and immune evasion. Understanding these pathways can inform vaccine and anti-infective strategies.
Metabolic and Glycosylation Disorders
Defects in nucleotide sugar metabolism can impair glycosylation, affecting protein function and extracellular matrix composition. UGDH and related enzymes are therefore studied in the context of glycosaminoglycan-related disorders [4,5].
From UDP-alpha-D-glucose metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does UGDH loss inhibit tumor growth? | UGDH knockout cancer cell line |
| How does cofactor binding regulate UGDH? | Point-mutation of allosteric residues |
| Can UDP-glucose pathway enzymes be redirected? | Knock-in of glycosyltransferase genes [6,7] |
| What is the role of UGDH in glycosaminoglycan synthesis? | Tagged knock-in for imaging |
| Can UDP-glucose supply be increased? | Overexpression of UGP2 [4,6] |
| Does CjUGD affect capsule formation? | Knockout in Campylobacter jejuni |
How to Study the UDP-alpha-D-glucose metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| NADH absorbance assay | UGDH enzyme activity | Inhibitor testing [1,5] |
| X-ray crystallography | Protein structure and ligand binding | Allosteric mechanism [2,5] |
| LC-MS metabolomics | UDP-glucose and UDP-glucuronate levels | Pathway flux [4,6] |
| Glycomics | Glycan composition | Glycosylation changes |
| CRISPR knockout screen | Gene essentiality | Cancer and glycosylation [1,6] |
| Enzymatic cascade assay | Glucoside production | Biocatalysis [7,8] |
| qPCR | Gene expression | Pathway regulation |
| Western blot | Protein levels | UGDH expression |
Enzyme Activity Assays
UDP-glucose dehydrogenase activity is measured spectrophotometrically by monitoring NADH production at 340 nm, as described in structural and kinetic studies [2,5]. These assays are used to test inhibitors and mutants [1,4].
Structural Biology
X-ray crystallography and cryo-EM reveal the active site and allosteric sites of UDP-glucose dehydrogenases, guiding inhibitor design [2,5]. Structural characterization of CalS8 provided insights into TDP-glucose dehydrogenase mechanism.
Metabolomics and Glycomics
LC-MS-based metabolomics quantifies UDP-glucose and UDP-glucuronate levels, while glycomics profiles glycosylation changes [4,6]. These methods assess pathway flux in cells and engineered microbes [7,8].
CRISPR Screening and Functional Genomics
CRISPR knockout screens can identify genes required for UDP-glucose-dependent glycosylation and cancer cell growth [1,6]. Pooled screens with glycosylation reporters enable discovery of pathway regulators.
How CRISPR Can Be Used to Study GO:0006011 UDP-alpha-D-glucose metabolic process
Knockout
CRISPR knockout of UGDH or UGP2 eliminates UDP-glucose metabolic flux, enabling tests of whether the pathway is required for cancer cell growth, glycosylation, or capsular polysaccharide production [1,3,4].
Point Mutation
Point mutations in UGDH catalytic or allosteric residues can dissect cofactor binding and enzyme activation, as suggested by structural studies. Such models help validate drug-target residues [1,4].
Knock-in
Knock-in of tagged UGDH or glycosyltransferases allows imaging and interaction studies in native chromatin context [4,6]. Knock-in of bacterial enzymes into E. coli enables glucosylation pathway engineering [6,7].
Overexpression
Overexpression of UGP2 or glucosyltransferases increases UDP-glucose supply and glucoside production in engineered microbes [6,7,8]. Overexpression in mammalian cells can test gain-of-function effects on glycosylation.
How EDITGENE Supports UDP-alpha-D-glucose metabolic process Research
Researchers studying UDP-alpha-D-glucose metabolic process-related genes often need to determine whether a candidate gene is causally involved in glycosylation, cancer growth, or microbial polysaccharide synthesis. EDITGENE provides CRISPR-based cell models and screening services to test these hypotheses rigorously.
Contact EDITGENE today to design your custom CRISPR model for UDP-alpha-D-glucose metabolic process research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| UGP2 Knockout HEK293 Cell Line | EDJ-KQ3343 | Human | 7360 | Details Get a Quote |
| ENTPD5 Knockout HEK293 Cell Line | EDJ-KQ4220 | Human | 957 | Details Get a Quote |
| GALT Knockout HEK293 Cell Line | EDJ-KQ17877 | Human | 2592 | Details Get a Quote |
| UGP2 Knockout A-549 Cell Line | EDJ-KQ24985 | Human | 7360 | Details Get a Quote |
| UGP2 Knockout HeLa Cell Line | EDJ-KQ24987 | Human | 7360 | Details Get a Quote |
| UGP2 Knockout HCT 116 Cell Line | EDJ-KQ23596 | Human | 7360 | Details Get a Quote |
| ENTPD5 Knockout A-549 Cell Line | EDJ-KQ25369 | Human | 957 | Details Get a Quote |
| ENTPD5 Knockout HCT 116 Cell Line | EDJ-KQ26685 | Human | 957 | Details Get a Quote |
| ENTPD5 Knockout HeLa Cell Line | EDJ-KQ26686 | Human | 957 | Details Get a Quote |
| GALT Knockout HeLa Cell Line | EDJ-KQ53303 | Human | 2592 | Details Get a Quote |
| GALT Knockout A-549 Cell Line | EDJ-KQ61787 | Human | 2592 | Details Get a Quote |
| GALT Knockout HCT 116 Cell Line | EDJ-KQ70268 | Human | 2592 | Details Get a Quote |
Displaying Records 1 To 12 Of 12 Records
Frequently Asked Questions About UDP-alpha-D-glucose metabolic process
What is UDP-alpha-D-glucose metabolic process?
It is the set of reactions involving UDP-alpha-D-glucose, an activated sugar donor used in glycosylation and polysaccharide synthesis [1,4].
What genes are involved in UDP-alpha-D-glucose metabolic process?
Key genes include UGDH, UGP2, and various glycosyltransferases such as UGT1A and UGT2B [1,4,6].
What does UGDH do in UDP-glucose metabolism?
UGDH oxidizes UDP-glucose to UDP-glucuronate, a precursor for glycosaminoglycans and drug conjugation [4,5].
Is UGDH a drug target?
Yes, UGDH is considered a potential drug target, and its inhibition reduces glioblastoma growth and migration [1,4].
How is UDP-glucose used in biotechnology?
Engineered microbes use UDP-glucose-dependent enzymes to glucosylate flavonoids and produce bioactive glucosides [6,7,8].
What diseases are linked to UDP-glucose metabolism?
Cancer, especially glioblastoma, and bacterial infections involving capsular polysaccharides are linked to this pathway [1,3].
How can I study UDP-glucose metabolism with CRISPR?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of pathway genes [1,5,6].
What methods measure UDP-glucose levels?
LC-MS metabolomics and enzyme activity assays are commonly used [4,5].
What is the role of UDP-glucose in glycosylation?
UDP-glucose serves as a glucose donor for glycosyltransferases that modify proteins, lipids, and small molecules [1,4].
Where can I get CRISPR models for UDP-glucose pathway genes?
EDITGENE provides knockout, point-mutation, knock-in, overexpression, and screening services for these genes [1,4,6].
Conclusion
UDP-alpha-D-glucose metabolic process (GO:0006011) is a central node in glycosylation, nucleotide sugar interconversion, and polysaccharide biosynthesis. Its key enzyme UGDH is a promising drug target in cancer, and the pathway is widely used in biocatalysis and microbial engineering [1,4,6,7,8]. CRISPR-based models and multi-omics methods now enable precise interrogation of this pathway in health and disease [1,5].
References
- 1. Oyinlade O et al.. 2018. Targeting UDP-α-D-glucose 6-dehydrogenase inhibits glioblastoma growth and migration.. Oncogene 37(20):2615-2629 PMID: 29479058
- 2. Singh S et al.. 2015. Structural Characterization of CalS8, a TDP-α-D-Glucose Dehydrogenase Involved in Calicheamicin Aminodideoxypentose Biosynthesis.. J Biol Chem 290(43):26249-58 PMID: 26240141
- 3. Simons ME et al.. 2023. Biosynthesis of UDP-β-l-Arabinofuranoside for the Capsular Polysaccharides of Campylobacter jejuni.. Biochemistry 62(20):3012-3019 PMID: 37737649
- 4. Egger S et al.. 2010. UDP-glucose dehydrogenase: structure and function of a potential drug target.. Biochem Soc Trans 38(5):1378-85 PMID: 20863317
- 5. Sennett NC et al.. 2012. Cofactor binding triggers a molecular switch to allosterically activate human UDP-α-D-glucose 6-dehydrogenase.. Biochemistry 51(46):9364-74 PMID: 23106432
- 6. Pandey RP et al.. 2014. Glucosylation of isoflavonoids in engineered Escherichia coli.. Mol Cells 37(2):172-7 PMID: 24599002
- 7. Shin JY et al.. 2016. In vitro single-vessel enzymatic synthesis of novel Resvera-A glucosides.. Carbohydr Res 424:8-14 PMID: 26918515
- 8. Thapa SB et al.. 2019. Cascade biocatalysis systems for bioactive naringenin glucosides and quercetin rhamnoside production from sucrose.. Appl Microbiol Biotechnol 103(19):7953-7969 PMID: 31407037
